ICU Medical (NASDAQ:ICUI) Posts Quarterly Earnings Results

ICU Medical (NASDAQ:ICUI) issued its earnings results on Thursday. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46, FiscalAI reports. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period in the previous year, the firm earned $2.10 EPS. The business’s revenue was up .5% on a year-over-year basis. ICU Medical updated its FY 2026 guidance to 8.600-9.000 EPS.

Here are the key takeaways from ICU Medical’s conference call:

• Second-quarter results exceeded expectations on earnings momentum, with organic revenue growth of 6%, adjusted EBITDA up 10% to $110 million, and adjusted EPS up 13% to $2.37.
• ICU Medical raised and narrowed its 2026 adjusted EBITDA guidance to $415 million–$435 million and adjusted EPS guidance to $8.60–$9.00, while increasing expected full-year adjusted gross margin to approximately 41.5%.
• Infusion Systems and Consumables delivered record sales, growing 12% and 5% organically, respectively. Management expects Systems organic growth at or above 6% in the near term and continued mid-single-digit growth in Consumables.
• Strong free cash flow of $62 million, including a $20 million tariff refund, enabled $50 million of debt repayment and reduced net leverage to 2.3 times; management remains on track for approximately 2 times leverage by year-end.
• The outlook still faces pressure from tariffs, unfavorable currencies, and higher oil and diesel costs, while Vital Care declined 4% organically and is expected to remain slightly down for the full year. Some pump installations occurred earlier than expected, and the timing of Medfusion 5000 FDA resubmission and CAD development remains uncertain.

ICU Medical Trading Up 10.9%

Shares of NASDAQ ICUI traded up $18.19 during trading on Friday, hitting $184.56. 931,233 shares of the company traded hands, compared to its average volume of 304,941. The firm has a market capitalization of $4.61 billion, a P/E ratio of 156.41, a P/E/G ratio of 2.58 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $151.64 and a 200-day moving average price of $141.02. ICU Medical has a 1 year low of $107.00 and a 1 year high of $192.85.

Analyst Ratings Changes

Several brokerages have recently issued reports on ICUI. BTIG Research upped their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Needham & Company LLC lifted their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday. Finally, Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $192.80.

Insider Transactions at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Several large investors have recently added to or reduced their stakes in ICUI. Smartleaf Asset Management LLC raised its position in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after purchasing an additional 101 shares during the period. Headlands Technologies LLC acquired a new stake in shares of ICU Medical in the second quarter valued at about $177,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of ICU Medical during the 4th quarter valued at about $203,000. Panagora Asset Management Inc. purchased a new position in ICU Medical in the 4th quarter worth approximately $205,000. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of ICU Medical during the fourth quarter valued at approximately $216,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.